Skip to main content
Orexo logo

Orexo — Investor Relations & Filings

Ticker · ORX ISIN · SE0000736415 LEI · 549300LJ5CCWDPTK9Z08 ST Manufacturing
Open in API
Filings indexed 843 across all filing types
Latest filing 2015-06-17 Share Issue/Capital Cha…
Country SE Sweden
Listing ST ORX

About Orexo

https://orexo.com/

Orexo is a commercial-stage pharmaceutical company focused on developing improved pharmaceuticals and digital therapies. The company addresses unmet patient needs, particularly within substance use disorders and mental health. It leverages proprietary drug delivery and formulation technologies to create innovative treatment solutions. Orexo's activities span research, development, and commercialization of its products.

Recent filings

Filing Released Lang Actions
Emission och återköp av C-aktier
Share Issue/Capital Change Classification · 1% confidence The document is a press release titled "Emission och återköp av C-aktier" (Issuance and repurchase of C-shares). It details a decision by Orexo AB to conduct a new share issue (nyemission) and immediately repurchase 135,000 C-shares as part of a performance-based incentive program (LTIP 2015). This action directly relates to changes in the company's capital structure, specifically involving the issuance and subsequent repurchase of shares. This aligns perfectly with the definition for 'Share Issue/Capital Change' (SHA) or potentially 'Transaction in Own Shares' (POS). Since the primary action described is the issuance (emission) followed by a repurchase related to an incentive plan, 'SHA' (Share Issue/Capital Change) is the most appropriate primary classification, although 'POS' (Transaction in Own Shares) is also highly relevant. Given the context of issuing shares for an incentive program, SHA is chosen as it covers the capital structure change aspect initiated by the issuance.
2015-06-17 Swedish
FDA approves the medium tablet strength, 2.9 mg/0.71 mg, of ZUBSOLV®
Regulatory Filings Classification · 1% confidence The document is explicitly titled "Press release" and announces that the FDA has approved a new dosage strength of the drug ZUBSOLV®. It contains quotes from the CEO, background information about the company (Orexo AB), and detailed safety information typical of a drug approval announcement. This is not a comprehensive annual report (10-K), an interim report (IR), or a formal regulatory filing like a proxy statement. It is a public announcement of a significant business/regulatory event (FDA approval) released to the market, which aligns best with an Earnings Release (ER) if it were quarterly results, but since it's a specific regulatory milestone announcement, it falls under the general category of a significant corporate announcement. Given the options, and since it's a press release announcing a major regulatory event (FDA approval) rather than financial results, it is most closely categorized as a general corporate announcement. However, in many financial databases, major product/regulatory news released via press release often falls under the 'Earnings Release' umbrella if it's the primary communication vehicle, or sometimes 'Regulatory Filings' (RNS) if it's not financial results. Since it is a press release announcing a major regulatory milestone (FDA approval) and not financial performance, it is best classified as a general Regulatory Filing (RNS) as it is a non-standard, significant corporate update that doesn't fit the specific financial report codes. It is not an ER because it is not reporting financial results (revenue, EPS, etc.). It is not an RPA because it is the news itself, not an announcement *about* another report being published. Therefore, RNS is the most appropriate fallback for a significant, non-financial regulatory/product announcement released as a press release.
2015-06-10 English
FDA godkänner en medium tablettstyrka (2,9 mg/0,71 mg) av Zubsolv®
Regulatory Filings Classification · 1% confidence The document is a press release ("Pressmeddelande") announcing that the FDA has approved a new medium tablet strength (2.9 mg/0.71 mg) of the drug Zubsolv®. This announcement details a regulatory milestone (FDA approval) and provides updates on product portfolio expansion and launch timelines. This type of announcement, which is a specific update on a product or regulatory event rather than a comprehensive financial report (like 10-K or IR) or a general regulatory filing fallback (RNS), fits best under the category for Capital/Financing Updates (CAP) if it were about fundraising, or more generally, a Regulatory Filing (RNS) if no other category fits. However, since it is a specific announcement about a regulatory approval impacting the product offering, and it is not a standard financial report, it is best classified as a general Regulatory Filing (RNS) as it is a specific, non-financial regulatory update that doesn't fit the other specific categories like DIRS, DIV, or MANG. Given the options, RNS serves as the best catch-all for specific regulatory news that isn't a core financial report or management change. The document length (4255 chars) is substantial enough that it is not just a brief announcement of an attached report (RPA).
2015-06-10 Swedish
Number of shares and votes in Orexo
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a short press release announcing a change in the total number of shares and votes in Orexo AB due to the exercise of warrants. This directly relates to the company's capital structure and share count. This fits the definition of 'Share Issue/Capital Change' (SHA), which covers changes in the number of shares. It is not a full financial report (10-K, IR), an earnings release (ER), or a dividend notice (DIV). Since it is a specific announcement about the share count changing, SHA is the most appropriate code.
2015-05-29 English
Antal aktier och röster i Orexo
Share Issue/Capital Change Classification · 1% confidence The document is a short press release (1415 characters) dated May 29, 2015, titled 'Antal aktier och röster i Orexo' (Number of shares and votes in Orexo). It explicitly states that the total number of shares and votes has changed due to the exercise of warrants and provides the new total count (34,399,723). This directly relates to a change in the company's capital structure or share count. This fits the definition of 'Share Issue/Capital Change' (SHA) better than a general regulatory filing (RNS) or a dividend notice (DIV). It is not a report itself, but a notification of a change in share count.
2015-05-29 Swedish
Orexo presenterar på Redeye Investor Forum i Göteborg
Regulatory Filings Classification · 1% confidence The document is a short announcement from Orexo stating that the CEO will present the company at the 'Redeye Investor Forum' on May 7, 2015. It provides details about the event and mentions where the presentation material will be available after the event. This is not a full financial report (like 10-K or IR), nor is it a formal regulatory filing about results (ER) or management changes (MANG). It is an announcement about the company's participation in an investor event, which aligns best with an Investor Presentation (IP) announcement or, given the context of announcing participation in an external forum, it could be considered a general announcement. However, since the core purpose is to inform investors about an upcoming presentation where company information will be shared, 'Investor Presentation' (IP) is the most fitting category, even though it's an announcement *about* a presentation rather than the presentation itself. Given the short length and the focus on an upcoming investor event, it is classified as IP.
2015-05-06 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.